Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + anlotinib + chemotherapy as neoadjuvant therapy for resectable stage II-III non-small cell lung cancer
ChiCTR2500100571Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and anlotinib in non-small cell lung cancer (NSCLC) and bronchial carcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Major pathologic response. Started Apr 2025; status: recruiting.
02
Drugs
adebrelimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2500100571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100571.